Ascidian's lab in Boston is developing a new kind of RNA editing therapy (Credit: Kevin Trimmer)
First-ever RNA editing trial in US gets clearance, pitting ‘exon editing’ technology against vision loss
The FDA told the Boston startup Ascidian Therapeutics that it can begin the first clinical tests of a therapy that “rewrites” RNA …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
